Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
Publishing timestamp: 2023-11-02 13:30:58
Summary
Novo Nordisk has stated that 80% of U.S. patients with insurance coverage who take Wegovy are paying less than $25 per month for the drug. This suggests that many insured Americans do not have to pay the full cost of the drug, which has a list price of around $1350. However, some health insurers are dropping obesity drugs like Wegovy from their plans due to their high cost. Novo Nordisk is hoping that new data demonstrating the heart health benefits of Wegovy will put more pressure on insurers to cover the medication.
Sentiment: MIXED
Tickers: NOVO.B-DK,
Keywords: health care industry, united states, business news, breaking news, business, biotech and pharmaceuticals, social issues, biotechnology, novo nordisk a/s, pharmaceuticals,
Source: https://www.cnbc.com/2023/11/02/wegovy-insured-patients-25-dollars-month.html